Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PRIMARY SCLEROSING CHOLANGITIS

Better end points needed in primary sclerosing cholangitis trials

A new study of a fibroblast growth factor 19 analogue in patients with primary sclerosing cholangitis (PSC) provides provocative results. The data challenge alkaline phosphatase levels as the appropriate surrogate end point in PSC trials and highlight alternatives, urging efforts to identify better clinical end points for this disease.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Research targets of new drugs for primary sclerosing cholangitis.

References

  1. Degirolamo, C., Sabbà, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51–69 (2016).

    Article  CAS  Google Scholar 

  2. Karlsen, T. H. et al. Primary sclerosing cholangitis – a comprehensive review. J. Hepatol. 67, 1298–1323 (2017).

    Article  Google Scholar 

  3. Zhou, M. et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 74, 3306–3316 (2014).

    Article  CAS  Google Scholar 

  4. Zhou, M. et al. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice. Hepatology 63, 914–929 (2016).

    Article  CAS  Google Scholar 

  5. Hirschfield, G. M. et al. Effect of NGM282, a FGF19 analogue, in primary sclerosing cholangitis: a multicentre, randomized, double-blind, placebo-controlled phase 2 trial. J. Hepatol. https://doi.org/10.1016/j.jhep.2018.10.035 (2018).

    Article  PubMed  Google Scholar 

  6. Ponsioen, C. Y. et al. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process. Hepatology 63, 1357–1367 (2016).

    Article  Google Scholar 

  7. Cheung, A. C. et al. Emerging pharmacologic therapies for primary sclerosing cholangitis. Curr. Opin. Gastroenterol. 33, 149–157 (2017).

    Article  CAS  Google Scholar 

  8. Fickert, P. et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J. Hepatol. 67, 549–558 (2017).

    Article  CAS  Google Scholar 

  9. Trivedi, P. J. et al. Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner. Gut 67, 1135–1145 (2018).

    Article  CAS  Google Scholar 

  10. Pinzani, M. & Luong, T. V. Pathogenesis of biliary fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 1279–1283 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pietro Invernizzi.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gerussi, A., Invernizzi, P. Better end points needed in primary sclerosing cholangitis trials. Nat Rev Gastroenterol Hepatol 16, 143–144 (2019). https://doi.org/10.1038/s41575-019-0110-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-019-0110-5

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing